Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A US National Health Care System? -- Ignore unavailable to you. Want to Upgrade?

To: TimF who wrote (4608)	2/19/2008 5:52:51 PM
From: J_F_Shepard	Read Replies (1) \| Respond to of 42652

" The point is that 48% of that world wide revenue comes from the US." You're still being deceptive.... US companies receive 48% of world wide revenue does not mean that all 48% comes from within the US.... And you continue to infer, if not outright claim, that the US funds all pharma R&D in the world. " Does the drug industry fund all pharmaceutical research? No. And no one is arguing that it does." You said, " Nothing specious about the idea that if nearly half the income comes from one country that it accounts for the lions share of the incentive for investments in R&D and testing. Investments are made in order to get a positive return. " A lion's share to me indicates more than 50%.... But in fact, US companies R&D accounts for 48.3% and Europe and Japan account for 51.7% of R&D world wide spending. It doesn't take a CPA to know that those with the highest revenues, and greatest profits would spend the greatest amount on R&D. It's a very complicated problem. But to continue to insist that the rest of the world is getting a free ride from the US is nothing but jingoism.